Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simplified Dosing of Indinavir, Nelfinavir, and Efavirenz in HIV
NCT00002235Phase 2Completed
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indinavir, nelfinavir and efavirenz in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co. Status: completed.
02
Drugs
indinavirnelfinavirefavirenz
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00002235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002235.